About this trial
Study hypothesis is that combining the advantages of hybrid PET/MRI and the high sensitivity/specificity of 16-alpha-18F-fluoro-17-beta-estradiol(FES), a radiolabeled form of estrogen binding to functionally active ER, the investigators could obtain a reliable, non-invasive, operator-independent, one-stage imaging method for staging LumA and ER-positive Lobular tumours.
Eligibility criteria
Qualifiers
Female patients, age>= 18 yrs, diagnosed with primary or advanced breast cancer
LumA or ER-positive Lobular subtypes
candidates to surgery as first treatment regardless of cN
ER-positive Her2 negative BC with ki67>10%
Disqualifiers
ER-negative tumors
Pregnancy;
Contraindication to PET;
Contraindication to MRI;
Trial design
Treatments tested in this trial
- FES
- PET/MRI A
- Translational analysis
Treatment groups
Sponsors and collaborators
Università Vita-Salute San Raffaele
Lead sponsor
IRCCS San Raffaele
Sponsor institution
IRCCS San Raffaele
Collaborator